Outcome
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Arunjyoti Bio Ventures reported a strong turnaround in Q1 FY26 (quarter ended 30 June 2025) with net sales of Rs 871.24 lakhs (up from Rs 528.10 lakhs in Q4 FY25) and a profit after tax of Rs 236.39 lakhs, compared to a loss of Rs 198.96 lakhs in the previous quarter. EPS stood at Rs 0.13 versus negative Rs 0.11 in Q4 FY25. The board approved re-appointment of three whole-time directors — Mr. Badari Narayana Murthy Pabbathi (holding 3.59 crore shares), his son Mr. Dathvik Pabbathi (holding 4.30 crore shares), and Mr. Nadimpalli Vishal — each for a 3-year term from 10 November 2025. The statutory auditor M/s V Ravi & Co. resigned citing pre-occupation after completing one 5-year term, and M/s PKF Sridhar & Santhanam LLP was appointed as the new statutory auditor for 5 years to fill the casual vacancy.
The swing from loss to profit signals improving operational performance and could be viewed positively by investors. The auditor change appears routine with no governance red flags noted, and the re-appointment of the promoter family and another director maintains continuity on the board.